One of the largest drug wholesalers in the United States agreed to merge with a major drug maker known for its generic products.
One of the largest drug wholesalers in the United States agreed to merge with a major drug maker known for its generic products.
Bergen Brunswig, Orange, CA, agreed to buy Ivax Corp., Miami, for $1.6 billion in a tax-free stock swap. The move represents the first time that a distributor has purchased a drug company in the United States.
The new company, BBI Healthcare Corp., will be located in Miami. Executives hope to create a generic line that can be bundled with its branded pharmaceutical and medical/surgical products. Combined, the market value of the two companies is about $3.2 billion.
"With the full integration of manufacturing and distribution, we can cut costs in the supply chain and help make health care more affordable," said Donald Roden, Bergen Brunswig's president and CEO-elect who will become CEO of the combined company. "Bergen Brunswig purchases nearly $2 billion in multisource pharmaceuticals each year. As part of BBI Healthcare, Ivax will be able to penetrate broad new markets and increase sales of its generic and proprietary pharmaceuticals."
Ivax will earn direct access to a network of more than 4,000 drug stores.
However, some pharmaceutical industry sources speculated that the merger might damage Ivax's relationship with other wholesalers.
The merger comes during hard times at Ivax. The company reported a third-quarter loss of $178.7 million, or $1.47 a share, compared with net income of $27.6 million, or 23 cents a share, in the same period a year earlier. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.